Endothelial dysfunction in HIV infection - The role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages

AIDS Reviews

Volumn 14, Issue 4, 2012, Pages 223-230

  López, Mariola ^a   San Román, Jesús ^b   Estrada, Vicente ^c   Vispo, Eugenia ^a   Blanco, Francisco ^a   Soriano, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Atherosclerosis; Circulating endothelial cell; Endothelial microparticle; Endothelial progenitor cell; Macrophage activation

Indexed keywords

BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; VIRUS REPLICATION;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL-DERIVED MICROPARTICLES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HIV SEROPOSITIVITY; HUMANS; HYPERTENSION; MACROPHAGES; MALE; RISK FACTORS; STEM CELLS;

EID: 84871641086     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Hsue P, Hunt P, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23:1059-67.
2. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22: F17-24.
3. Funderburg N, Mayne E, Sieg S, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010;115:161-7.
4. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24:243-53.
5. Moreno P, Sanz J, Fuster V. Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J Am Coll Cardiol. 2009;53:2315-23.
6. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-6.
7. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circul Res. 2001;89:e1-7.
8. Valgimigli M, Rigolin G, Fucili A, et al. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation. 2004;110:1209-12. (Pubitemid 39202334)
9. Chironi G, Walch L, Pernollet MG, et al. Decreased number of circulating CD34-KDR cells in asymptomatic subjects with preclinical atherosclerosis. Atherosclerosis. 2007;191:115-20. (Pubitemid 46237627)
10. Kunz G, Liang G, Cuculi F, et al. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J. 2006;152:190-5. (Pubitemid 43974737)
11. Hill J, Zalos G, Halcox J, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348: 593-600. (Pubitemid 36204953)
12. Werner N, Wassmann S, Ahlers P, et al. Endothelial progenitor cells correlate with endothelial function in patients with coronary artery disease. Basic Res Cardiol. 2007;102:565-71. (Pubitemid 47578401)
13. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007. (Pubitemid 41262334)
14. da Silva E, Fonseca F, França C, et al. Imbalance between endothelial progenitors cells and microparticles in HIV-infected patients naive for antiretroviral therapy. AIDS. 2011;25:1595-601.
15. López M, Vispo E, San Román J, et al. High risk of endothelial dysfunction in HIV individuals may result from deregulation of circulating endothelial cells and endothelial progenitor cells. AIDS Res Hum Retroviruses. 2012;28:656-9.
16. Costiniuk C, Hibbert B, Filion L, et al. Circulating endothelial progenitor cell levels are not reduced in HIV-infected men. J Infect Dis. 2012;205:713-7.
17. Teofili L, Iachininoto M, Capodimonti S, et al. Endothelial progenitor cell trafficking in HIV-infected persons. AIDS. 2010;24:2443-50.
18. Papasavvas E, Hsue P, Reynolds G, et al. Increased CD34+/KDR+ cells are not associated with carotid intima-media thickness progression in chronically HIV-1-positive subjects. Antivir Ther. 2012;17:557-63.
19. Blann A, Woywodt A, Bertolini F, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost. 2005;93:228-35. (Pubitemid 40253726)
20. Makin A, Blann A, Chung N, Silverman S, Lip G. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur Heart J. 2004;25:371-6. (Pubitemid 38391518)
21. Chong A, Blann A, Patel J, Freestone B, Hughes E, Lip G. Endothelial dysfunction and damage in congestive heart failure: relation of flowmediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation. 2004;110:1794-8. (Pubitemid 39302656)
22. Boulanger C, Amabile N, Tedgui A. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension. 2006;48:180-6. (Pubitemid 44309805)
23. Puddu P, Puddu G, Cravero E, Muscari S, Muscari A. The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol. 2010;26:140-5.
24. Sinauridze E, Kireev D, Popenko N, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost. 2007;97:425-34. (Pubitemid 46437805)
25. Morel O, Jesel L, Freyssinet J, et al. Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis. Thromb J. 2005;3:15.
26. Mayne E, Funderburg N, Sieg S, et al. Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr. 2012;59:340-6.
27. Corrales-Medina V, Simkins J, Chirinos J, et al. Increased levels of platelet microparticles in HIV-infected patients with good response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2010;54:217-18.
28. Bulut D, Maier K, Bulut-Streich N, Borgel J, Hanefeld C, Mugge A. Circulating endothelial microparticles correlate inversely with endothelial dysfunction in patients with ischemic left ventricular dysfunction. J Card Failure. 2008;14:336-40. (Pubitemid 351636235)
29. Pirro M, Schillaci G, Paltriccia R, et al. Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Atheroscler Thromb Vasc Biol. 2006;26:2530-5. (Pubitemid 44607476)
30. Bussolino F, Mitola S, Serini G, Barillari G, Ensoli B. Interactions between endothelial cells and HIV-1. Int J Biochem Cell Biol. 2001;33:371-90. (Pubitemid 32324005)
31. Ren Z, Yao Q, Chen C. HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells. Lab Invest. 2002;82:245-55. (Pubitemid 34242518)
32. Swirski F, Libby P, Aikawa E, et al. Ly-6chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117:195-205. (Pubitemid 46048466)
33. Moreno P, Purushothaman K, Sirol M, Levy A, Fuster V. Neovascularization in human atherosclerosis. Circulation. 2006;113:2245-52.
34. Graversen J, Madsen M, Moestrup S. CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int J Biochem Cell Biol. 2002;34:309-14. (Pubitemid 34164272)
35. Hintz K, Rassias A, Wardwell K, et al. Endotoxin induces rapid metal-loproteinase- mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor cd163. J Leukoc Biol. 2002;72:711-17. (Pubitemid 36277842)
36. Moreno J, Ortega-Gómez A, Delbosc S, et al. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis. Eur Heart J. 2012;33:252-63.
37. Moreno J, Muñoz-García B, Martín-Ventura J, et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis. 2009;207:103-10.
38. Hsue P, Lo J, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603-8. (Pubitemid 38451715)
39. Hsue P, Ordovas K, Lee T, et al. Carotid intima-media thickness among HIV-infected patients without coronary calcium. Am J Cardiol. 2012;109:742-7.
40. Funderburg N, Mayne E, Sieg S, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010;115:161-7.
41. Hsue P, Hunt P, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006;20:2275-83. (Pubitemid 44789529)
42. Crowe S, Westhorpe C, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol. 2010;87:589-98.
43. Douek D, Brenchley J, Betts M, et al. HIV preferentially infects HIVspecific CD4+ T cells. Nature. 2002;417:95-8. (Pubitemid 34498823)
44. Brenchley J, Price D, Schacker T, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-71. (Pubitemid 44924494)
45. Burdo T, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with non-calcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204: 1227-36.
46. Glomset J. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-67.
47. Wang X, Collins H, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117:2216-24. (Pubitemid 47219566)
48. Amit V, Khera M, Cuchel M, et al. Cholesterol efflux capacity, highdensity lipoprotein function, and atherosclerosis. N Engl J Med. 2011; 364:127-35.
49. Honor R, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2008;199:79-86. (Pubitemid 351842701)
50. Mujawar Z, Rose H, Morrow M, et al. HIV impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006;4:e365.
51. Micheletti R, Fishbein G, Fishbein M, et al. Coronary atherosclerotic lesions in HIV-infected patients: a histopathologic study. Cardiovasc Pathol. 2009;18:28-36.
52. Asztalos B, Mujawar Z, Morrow M, et al. Circulating Nef induces dyslipidemia in SIV-infected macaques by suppressing cholesterol efflux. J Infect Dis. 2010;202:614-23.
53. Mukhamedovaa N, Honor R, Huanhuan L, et al. Antiretroviral compounds and cholesterol efflux from macrophages. Atherosclerosis. 2009;206:439-43.
54. Walter D, Rittig K, Bahlmann F, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002; 105:3017-24. (Pubitemid 34693836)
55. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885-90. (Pubitemid 32578123)
56. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111:2356-63. (Pubitemid 40647072)
57. Moiseeva O, Karelkina E, Moroshkin V, Seliutin A, Shliakhto E. Effect of therapy with rosuvastatin on circulating endothelial progenitor cells in patients with chronic heart failure. Kardiologia. 2009;49:11-15.
58. Tousoulis D, Andreou I, Tsiatas M, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214:151-7.
59. Laufs U, La Fata V, Plutzky J, Liao J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-35. (Pubitemid 28152885)
60. Landmesser U, Engberding N, Bahlmann F, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004;110:1933-9. (Pubitemid 39331904)
61. Fadini G, Albiero M, Boscaro E, et al. Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. Cell Biol Int. 2010;34:709-15.
62. Shimada T, Takeshita Y, Murohara T, et al. Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation. 2004;110:1148-55. (Pubitemid 39328204)
63. De Wit S, Delforge M, Necsoi CV, Clumeck N. Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS. 2011;19;25:1332-3.
64. Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203:756-64.
65. Leung P, Wang S, Lu S, Chou W, Shiau C, Chou T. Simvastatin inhibits pro-inflammatory mediators through induction of heme oxygenase-1 expression in lipopolysaccharide-stimulated RAW264.7 macrophages. Toxicol Lett. 2011;207:159-66.